Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of dapagliflozin on serum magnesium in ADTKD-HNF1B patients with renal hypomagnesemia
2022-000596-40Phase 3Active
- Sponsor
- Radboudumc
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of dapagliflozin in autosomal dominant tubulointerstitial kidney disease (ADTKD) and Magnesium wasting, sponsored by Radboudumc. Primary endpoint: Change in serum magnesium. Started Mar 2022; status: active.
02
Drugs
dapagliflozin
03
Conditions
autosomal dominant tubulointerstitial kidney disease (ADTKD)Magnesium wasting
Beyond the preview
Go deeper on 2022-000596-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000596-40.